The JNCI Podcast

Podcast with Dr. Christine Ambrosone and Dr. David Cheng

Dr. Eric Winer discusses his editorial, “Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway,” published in JNCI (December 2017).

JNCI author Dr. Kurian explains her recent paper in JNCI.

Author interview with Dr. Dawn L. Hershman

A podcast with JNCI author Daniel Joben.

Dr. Ashish Deshmukh and Dr, Anna Likhacheva discusses their recent paper, “Cost-Effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer" (June 2017)

A JNCI Podcast with Curtis Harris

Dr. Judy Garber, of the Dana Farber Cancer Institute in Boston, discusses how family cancer history should be integrated into personalized patient care.

Dr. Avrum Spira discusses his recent paper, " Shared Gene Expression Alterations in Nasal and Bronchial Epithelium for Lung Cancer Detection " (May 2017)

Mohammad Asim discusses the use of choline kinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target

Lapo Sali discusses reduced and full-preparation CT colonography, fecal immunochemical test, and colonoscopy for population screening of colorectal cancer

Erika Loftfield discusses how drinking coffee may be associated with a lower risk of malignant melanoma

Carrie Bennette discusses factors predicting low patient accrual in cancer clinical trials

Leroy Hood discusses the future of cancer research

Vincent Devita discusses the future of cancer research

Heinz-Josef Lenz discusses his study about using the location of primary tumors as a prognostic factor in metastatic colorectal cancer

David Gerber discusses the effects of prior cancer on outcomes in advanced lung cancer

Martine Moossdorff talks about creating a consensus group of international breast cancer experts to come up with definitions for certain breast cancer terms

DeAnn Lazovich discusses exposure to indoor tanning and melanoma risk

Khalid Shah discusses his study on stem cells

Martin Tammemägi discusses the impact of lung cancer screening results on smoking cessation

Paul Frankel discusses baseline selenium and prostate cancer risk

Isra G. Levy M.B., BCh., MSc., talks about the health risks and benefits of aspirin use.

Dr. Lesley Rushton discusses how miners exposed to high levels of diesel exhaust in various mining facilities in the U.S. have a higher risk of lung cancer incidence and mortality than the general population.

Listen to summaries of the studies and news stories from Issue 12.

Listen to summaries of the studies and news stories from Issue 10.

Listen to summaries of the studies and news stories from Issue 11.

Dr. Jeffrey Schlom talks about therapeutic cancer vaccines

Dr. Michael Gnant of the Medical University of Vienna discusses data showing positive results on zoledronic acid and endocrine therapy for premenopausal breast cancer patients at the San Antonio Breast Cancer Symposium held Dec. 6-10.

Summaries of the News Stories from JNCI Volume 103 Issue 24.

Summaries of the News Stories from JNCI Volume 103 Issue 23.

Dr. Douglas McNeel discusses early stage studies on DNA vaccines for castrate resistant prostate cancer ahead of his presentation of the study results at the Society for Immunotherapy of Cancer annual meeting in Bethesda, held Nov. 4-6.

Dr. Ole-Petter Hamnvik discusses antineoplastic agents such as immunotherapies and targeted therapies that specifically target signaling pathways in cancer cells are associated with thyroid dysfunction.

Summaries of the News Stories from JNCI Volume 103 Issue 21.

Dr. Gordon Mills elaborates on his lecture on molecular personalized medicine at the recent ECCO-ESMO Cancer Congress in Stockholm.

Dr. Chris Parker, lead investigator of the international ALSYMPCA trial of radium 223 (Alpharadin) for bone metastases in advanced prostate cancer, discusses the trial and future of this therapy following his lecture at the recent ECCO-ESMO Cancer Congress in Stockholm.

Dr. Eduardo Franco discusses a study showing that one and two doses of HPV vaccines are just as effective as three doses for decreasing the risk of cervical cancer.

Dr. Kathy Helzlsouer, of the Prevention and Research Center at Mercy Medical Center in Baltimore, discusses breast cancer risk prediction models based on findings from a study of a cohort of Italian women.

Dr. Jennifer Vidrine, of the University of Texas MD Anderson Cancer Center, discusses active and passive recruitment methods for smoking quitlines.

Dr. Joan Warren, of the National Cancer Institute, conducted a study that compared end-of-life care for lung cancer patients in Ontario and the U.S.

Dr. Judy Garber, of the Dana Farber Cancer Institute in Boston, discusses how family cancer history should be integrated into personalized patient care.

Dr. Lisa Kachnic, of Boston University Medical Center, discusses how the growing usage of IMRT, or intensity-modulated radiation therapy, for breast cancer is mostly taking place in parts of the country where the procedure is reimbursed.

Dr. Brenda Edward, one of the authors of the Annual Report to the Nation on cancer trends in the U.S., discusses this year's report, which focuses on brain tumors. The Report showed an overall decline in cancer mortality rates.

Dr. Otis Brawley discusses a study on PSA velocity showing that using PSA velocity as a prostate cancer marker would not improve patient outcomes and would lead to a large number of unnecessary biopsies

Dr. Interview with Dr. Philip Glass

Dr. Patricia Ganz of UCLA discusses a review of breast cancer clinical trials that included quality of life measures as endpoints.

Dr. Matthew Mealiffe discusses a cohort study from the Women's Health Initiative that combines the usage of the Gail model and SNPs (single nucleotide polymorphisms) to prevent breast cancer risk.

Dr. Rowan Chlebowski discusses an observational study from the Women's Health Initiative showing estrogen usage among post-menopausal women does not increase lung cancer incidence and mortality.